Market Overview

UPDATE: Morgan Stanley Reiterates On McKesson Following Investor Day

Share:
Related MCK
Generic Drug Price Deflation Is Weighing On McKesson Shares
Goldman Drops McKesson To Neutral, Sees Limited Upside
Please Fill My Rx For McKesson Corporation (Seeking Alpha)

In a report published Thursday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on McKesson (NYSE: MCK), and raised the price target from $197.00 to $205.00.

In the report, Morgan Stanley noted, “Investor day showcased MCK's mkt leadership, favorable ind trends and mgmt breadth. Incr margin targets highlight expansion levers, complemented by cap deployment. W/ strong generic inflation, Celesio & PSS synergies, and generic scale oppty, we view MCK as best positioned in group. PT to $205.”

McKesson closed on Wednesday at $187.35.

Latest Ratings for MCK

DateFirmActionFromTo
Sep 2016Goldman SachsDowngradesBuyNeutral
Aug 2016JP MorganMaintainsOverweight
Jul 2016Morgan StanleyMaintainsOverweight

View More Analyst Ratings for MCK
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Ricky R. GoldwasserAnalyst Color Price Target Analyst Ratings

 

Related Articles (MCK)

View Comments and Join the Discussion!